Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care. 

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

Radiation therapy produced superior HRQOL outcomes and fewer toxicities vs endocrine therapy in older patients with stage I luminal-like breast cancer.

Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer

Ultra-sensitive tissue-free ctDNA testing showed that baseline ctDNA was associated with larger pathological tumor size in HR-positive breast cancer.

Baseline ctDNA Is Associated With Larger Pathological Tumors in HR+ Early Breast Cancer

Elacestrant increased real-world TTNT for patients with ESR1-mutant HR-positive/HER2-negative breast cancer vs PFS from the phase 3 EMERALD trial. 

Elacestrant Improves Real-World Time to Next Treatment or Treatment Discontinuation in ESR1+ HR+/HER2– Breast Cancer

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

The PACIFIC-5 study has met its primary end point of improved PFS with consolidation durvalumab after CRT in select unresectable stage III NSCLC.

Consolidation Durvalumab Improves PFS in Unresectable Stage III NSCLC Without Progression After CRT

A person’s “biological age” may be a hidden factor in their risk of colorectal cancer before the age of 50.

Biological Age as a Tool to Predict Early-Onset Colorectal Cancer Risk

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Dostarlimab received breakthrough therapy designation from the FDA for locally advanced dMMR/MSI-H rectal cancer.

FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer 

Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL. 

Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Advancements in the Management of Ovarian Cancer 

Brief Overview of Frontline Maintenance Therapy for Advanced Ovarian Cancer

Video content above is prompted by the following:

: Briefly review frontline maintenance therapy options for advanced ovarian cancer and highlight the key factors that guide your choice between available therapies.

How does a patient’s HRD status influence your selection of maintenance therapy?

Under what circumstances would you consider a combination approach with PARP inhibitors and bevacizumab vs using monotherapy?

Videos

Panelists discuss how recent advancements in ovarian cancer treatment, including biomarker-guided therapy, PARP inhibitors, combination therapies, and antibody-drug conjugates, are shaping personalized management strategies to improve patient outcomes.

Panelists discuss how biomarker testing for advanced ovarian cancer, including when and which biomarkers to test (such as HRD), plays a crucial role in guiding treatment decisions and personalizing patient care.

Biomarker Testing in Advanced Ovarian Cancer

Panelists discuss how genomic instability scores, including HRD vs HRP profiles, influence treatment selection and sequencing in ovarian cancer, particularly in guiding the use of PARP inhibitors and other targeted therapies in the maintenance setting, and how these scores may prompt adjustments to standard treatment approaches.

Role of Genomic Instability Scores in Treatment Selection

Panelists discuss how frontline maintenance therapy options for advanced ovarian cancer are influenced by key factors, such as a patient’s HRD status, and when a combination approach with PARP inhibitors and bevacizumab might be preferred over monotherapy.

Brief Overview of Frontline Maintenance Therapy for Advanced Ovarian Cancer

EP: 1.Biomarker Testing in Advanced Ovarian Cancer

EP: 2.Role of Genomic Instability Scores in Treatment Selection

EP: 3.Brief Overview of Frontline Maintenance Therapy for Advanced Ovarian Cancer

Latest Conference Coverage